https://assets.capyfin.com/instruments/678fdc13234e27009c5d577b.png avatar
SIGA Technologies
🇺🇸 NASDAQ:SIGA
View Company
OverviewEarningsDividends
•
Mar 31, 2023

SIGA Technologies Q1 2023 Earnings Report

SIGA Technologies' financial performance declined in Q1 2023, with decreased revenues and a net loss, despite progress in oral TPOXX sales to the U.S. Department of Defense.

Key Takeaways

SIGA Technologies reported a decrease in total revenues to $8.3 million for the three months ended March 31, 2023, compared to $10.5 million for the same period in 2022. The company experienced a net loss of $0.9 million, with a diluted loss per share of $0.01. Despite the overall loss, SIGA is targeting significant oral TPOXX deliveries to the DoD and SNS throughout 2023.

Total revenues decreased to $8.3 million compared to $10.5 million year-over-year.

Net loss was $0.9 million, with a diluted loss per share of $0.01.

Operating loss was $2.1 million, compared to $1.4 million in the prior year.

Targeting $11 million of oral TPOXX deliveries to the DoD in 2023, including $5 million in Q1, and approximately $113 million of oral TPOXX deliveries to the SNS.

Total Revenue
$8.32M
Previous year: $10.5M
-21.0%
EPS
-$0.01
Previous year: -$0.01
+0.0%
Gross Profit
$2.13M
Cash and Equivalents
$116M
Previous year: $153M
-24.5%
Total Assets
$184M

SIGA Technologies

SIGA Technologies

SIGA Technologies Revenue by Segment

Forward Guidance

SIGA Technologies is targeting approximately $11 million of oral TPOXX deliveries to the DoD and approximately $113 million of oral TPOXX deliveries to the SNS in 2023.

Positive Outlook

  • Targeting $11 million of oral TPOXX deliveries to the DoD in 2023.
  • Targeting approximately $113 million of oral TPOXX deliveries to the SNS in 2023.
  • Working to build and meet demand for oral TPOXX across geographic regions.
  • Continuing to work toward deliveries of IV TPOXX to the SNS this year.
  • Company announced a special cash dividend of $0.45 per share.

Challenges Ahead

  • Risk that BARDA may not exercise all remaining unexercised options under the BARDA Contract.
  • Risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms.
  • Risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX.
  • Risk that the U.S. or foreign governments' responses to national or global economic conditions or infectious diseases are ineffective.
  • Risk associated with responding to the current mpox outbreak.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View SIGA Technologies